Publication

Serum S100B in elderly patients with and without delirium

van Munster, B. C., Korevaar, J. C., Korse, C. M., Bonfrer, J. M., Zwinderman, A. H. & de Rooij, S. E., Mar-2010, In : International Journal of Geriatric Psychiatry. 25, 3, p. 234-239 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Munster, B. C., Korevaar, J. C., Korse, C. M., Bonfrer, J. M., Zwinderman, A. H., & de Rooij, S. E. (2010). Serum S100B in elderly patients with and without delirium. International Journal of Geriatric Psychiatry, 25(3), 234-239. https://doi.org/10.1002/gps.2326

Author

van Munster, Barbara C. ; Korevaar, Johanna C. ; Korse, Catharina M. ; Bonfrer, Johannes M. ; Zwinderman, Aeilko H. ; de Rooij, Sophia E. / Serum S100B in elderly patients with and without delirium. In: International Journal of Geriatric Psychiatry. 2010 ; Vol. 25, No. 3. pp. 234-239.

Harvard

van Munster, BC, Korevaar, JC, Korse, CM, Bonfrer, JM, Zwinderman, AH & de Rooij, SE 2010, 'Serum S100B in elderly patients with and without delirium', International Journal of Geriatric Psychiatry, vol. 25, no. 3, pp. 234-239. https://doi.org/10.1002/gps.2326

Standard

Serum S100B in elderly patients with and without delirium. / van Munster, Barbara C.; Korevaar, Johanna C.; Korse, Catharina M.; Bonfrer, Johannes M.; Zwinderman, Aeilko H.; de Rooij, Sophia E.

In: International Journal of Geriatric Psychiatry, Vol. 25, No. 3, 03.2010, p. 234-239.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Munster BC, Korevaar JC, Korse CM, Bonfrer JM, Zwinderman AH, de Rooij SE. Serum S100B in elderly patients with and without delirium. International Journal of Geriatric Psychiatry. 2010 Mar;25(3):234-239. https://doi.org/10.1002/gps.2326


BibTeX

@article{7dd7d76ecf3146c490c59f8c4721d9b5,
title = "Serum S100B in elderly patients with and without delirium",
abstract = "Objective: Elevation of S100B has been shown after various neurologic diseases with cognitive dysfunction. The aim of this study was to compare the serum level of S100B of patients with and without delirium and investigate the possible associations with different subtypes of delirium.Methods: Acutely admitted medical patients aged 65 years or more were included from 2005 through 2008. Delirium was diagnosed by Confusion Assessment Method, delirium subtype by Delirium Symptom Interview and preexistent global cognitive function by the 'Informant Questionnaire on Cognitive Decline-short form'. S100B levels were determined in serum by electrochemiluminescence immunoassay.Results: Samples of 412 patients were included, 91 during delirium, 35 after delirium and 286 of patients without delirium. Patients with delirium (31%) were significantly older, 81.5 versus 76.6 years (p <0.001) and experienced significantly more often preexistent cognitive and functional impairment (p <0.001). S100B level differed significantly (p = 0.004) between the three groups: median 0.07 mu g/L (inter-quartile ranges: 0.05-0.14 mu g/L) during delirium, 0.12 mu g/L (0.05-0.29 mu g/L) after delirium and 0.06 mu g/L (0.03-0.10 mu g/L) in patients without delirium. Combining the impact of cognitive impairment, infection and age on S100B, highest S100B was observed in the oldest patients after delirium with preexistent cognitive impaired and infection. Delirium subtype and S100B level were not significantly correlated.Conclusion: Higher S100B levels were found in patients with delirium than in patients without delirium, with highest levels of S100B in samples taken after delirium. Future studies are needed to elucidate the mechanism responsible for the increase of S100B and the possible association with long term cognitive impairment. Copyright (C) 2009 John Wiley & Sons, Ltd.",
keywords = "S100B, elderly, delirium, medical, marker, brain damage, NEURON-SPECIFIC ENOLASE, DUTCH VERSION, RATING-SCALE, VALIDATION, DEMENTIA, SUBTYPES, DISEASE, SURGERY, MARKER, IQCODE",
author = "{van Munster}, {Barbara C.} and Korevaar, {Johanna C.} and Korse, {Catharina M.} and Bonfrer, {Johannes M.} and Zwinderman, {Aeilko H.} and {de Rooij}, {Sophia E.}",
year = "2010",
month = mar,
doi = "10.1002/gps.2326",
language = "English",
volume = "25",
pages = "234--239",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - Serum S100B in elderly patients with and without delirium

AU - van Munster, Barbara C.

AU - Korevaar, Johanna C.

AU - Korse, Catharina M.

AU - Bonfrer, Johannes M.

AU - Zwinderman, Aeilko H.

AU - de Rooij, Sophia E.

PY - 2010/3

Y1 - 2010/3

N2 - Objective: Elevation of S100B has been shown after various neurologic diseases with cognitive dysfunction. The aim of this study was to compare the serum level of S100B of patients with and without delirium and investigate the possible associations with different subtypes of delirium.Methods: Acutely admitted medical patients aged 65 years or more were included from 2005 through 2008. Delirium was diagnosed by Confusion Assessment Method, delirium subtype by Delirium Symptom Interview and preexistent global cognitive function by the 'Informant Questionnaire on Cognitive Decline-short form'. S100B levels were determined in serum by electrochemiluminescence immunoassay.Results: Samples of 412 patients were included, 91 during delirium, 35 after delirium and 286 of patients without delirium. Patients with delirium (31%) were significantly older, 81.5 versus 76.6 years (p <0.001) and experienced significantly more often preexistent cognitive and functional impairment (p <0.001). S100B level differed significantly (p = 0.004) between the three groups: median 0.07 mu g/L (inter-quartile ranges: 0.05-0.14 mu g/L) during delirium, 0.12 mu g/L (0.05-0.29 mu g/L) after delirium and 0.06 mu g/L (0.03-0.10 mu g/L) in patients without delirium. Combining the impact of cognitive impairment, infection and age on S100B, highest S100B was observed in the oldest patients after delirium with preexistent cognitive impaired and infection. Delirium subtype and S100B level were not significantly correlated.Conclusion: Higher S100B levels were found in patients with delirium than in patients without delirium, with highest levels of S100B in samples taken after delirium. Future studies are needed to elucidate the mechanism responsible for the increase of S100B and the possible association with long term cognitive impairment. Copyright (C) 2009 John Wiley & Sons, Ltd.

AB - Objective: Elevation of S100B has been shown after various neurologic diseases with cognitive dysfunction. The aim of this study was to compare the serum level of S100B of patients with and without delirium and investigate the possible associations with different subtypes of delirium.Methods: Acutely admitted medical patients aged 65 years or more were included from 2005 through 2008. Delirium was diagnosed by Confusion Assessment Method, delirium subtype by Delirium Symptom Interview and preexistent global cognitive function by the 'Informant Questionnaire on Cognitive Decline-short form'. S100B levels were determined in serum by electrochemiluminescence immunoassay.Results: Samples of 412 patients were included, 91 during delirium, 35 after delirium and 286 of patients without delirium. Patients with delirium (31%) were significantly older, 81.5 versus 76.6 years (p <0.001) and experienced significantly more often preexistent cognitive and functional impairment (p <0.001). S100B level differed significantly (p = 0.004) between the three groups: median 0.07 mu g/L (inter-quartile ranges: 0.05-0.14 mu g/L) during delirium, 0.12 mu g/L (0.05-0.29 mu g/L) after delirium and 0.06 mu g/L (0.03-0.10 mu g/L) in patients without delirium. Combining the impact of cognitive impairment, infection and age on S100B, highest S100B was observed in the oldest patients after delirium with preexistent cognitive impaired and infection. Delirium subtype and S100B level were not significantly correlated.Conclusion: Higher S100B levels were found in patients with delirium than in patients without delirium, with highest levels of S100B in samples taken after delirium. Future studies are needed to elucidate the mechanism responsible for the increase of S100B and the possible association with long term cognitive impairment. Copyright (C) 2009 John Wiley & Sons, Ltd.

KW - S100B

KW - elderly

KW - delirium

KW - medical

KW - marker

KW - brain damage

KW - NEURON-SPECIFIC ENOLASE

KW - DUTCH VERSION

KW - RATING-SCALE

KW - VALIDATION

KW - DEMENTIA

KW - SUBTYPES

KW - DISEASE

KW - SURGERY

KW - MARKER

KW - IQCODE

U2 - 10.1002/gps.2326

DO - 10.1002/gps.2326

M3 - Article

VL - 25

SP - 234

EP - 239

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 3

ER -

ID: 34079941